In vitro evaluation of doxorubicin-eluting porous titania microspheres for transcatheter arterial chemoembolization
Source abstract
Abstract
Preparing drug-eluting beads (DEBs) from radiopaque materials such as titania (TiO2) can meet clinical need for directly visualizing DEBs during drug-eluting bead transcatheter arterial chemoembolization (DEB-TACE). Porous anatase-type TiO2 microspheres with mean volume diameters of approximately 30 µm were obtained when silica nanoparticles (SiNPs) were introduced into the TiO2 matrix by a sol–gel process involving a water-in-oil emulsion, and the SiNPs were then dissolved by subsequent treatment with NaOH solution. Of special note, microspheres prepared using SiNPs of approximately 20 – 25 nm in diameter had a high specific surface area of ~120 m2·g−1 and a high doxorubicin (DOX)-adsorption capacity of ~150 mg·mL−1, and they gradually released ~10% of the adsorbed DOX within 5 days. The DOX-loaded microspheres were non-cytotoxic, moreover, and exerted anticancer effects on HeLa cells. We propose that the present TiO2 microspheres are potentially useful as novel radiopaque embolic materials for DEB-TACE.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Hepatocellular Carcinoma Treatment and Prognosis · Lanthanide and Transition Metal Complexes · Vascular Procedures and Complications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan
Graduate School of Biomedical Engineering, Tohoku University, Sendai, Japan
Graduate School of Engineering, Tohoku University, Sendai, Japan
Graduate School of Dentistry, Tohoku University, Sendai, Japan
References (31)
Show source-provided references
1. 10.1002/ijc.2551610.1002/ijc.25516 ↗
2. 10.1007/s00270-007-9280-610.1007/s00270-007-9280-6 ↗
3. 10.1159/00034588610.1159/000345886 ↗
4. 10.1016/S1051-0443(98)70398-710.1016/S1051-0443(98)70398-7 ↗
5. 10.1097/01.RVI.0000124952.24134.8B10.1097/01.RVI.0000124952.24134.8B ↗
6. 10.1097/01.RVI.0000195323.46152.B310.1097/01.RVI.0000195323.46152.B3 ↗
7. 10.1007/s00270-008-9409-210.1007/s00270-008-9409-2 ↗
8. 10.1016/j.jvir.2014.04.00510.1016/j.jvir.2014.04.005 ↗
9. 10.1007/s00270-009-9711-710.1007/s00270-009-9711-7 ↗
10. 10.7150/thno.1313710.7150/thno.13137 ↗
11. 10.2109/jcersj2.121.78210.2109/jcersj2.121.782 ↗
12. 10.1016/j.msec.2015.02.01710.1016/j.msec.2015.02.017 ↗
13. 10.1007/s10971-015-3680-x10.1007/s10971-015-3680-x ↗
14. 10.1002/jbm.b.3376510.1002/jbm.b.33765 ↗
15. 10.1007/s10856-012-4735-y10.1007/s10856-012-4735-y ↗
16. 10.2353/jmoldx.2008.07013110.2353/jmoldx.2008.070131 ↗
17. 10.1016/0022-3093(82)90250-210.1016/0022-3093(82)90250-2 ↗
18. 10.1021/j100055a03510.1021/j100055a035 ↗
19. 10.1039/c2ay25474c10.1039/c2ay25474c ↗
20. 10.1006/jcat.1995.111810.1006/jcat.1995.1118 ↗
21. 10.1016/0142-9612(81)90059-410.1016/0142-9612(81)90059-4 ↗
22. 10.1016/j.ijpharm.2010.10.03710.1016/j.ijpharm.2010.10.037 ↗
23. 10.1021/am405442n10.1021/am405442n ↗
24. Suyama S · J Ceram Soc Japan · 1978 · 86 · 119
25. 10.1111/j.1151-2916.2001.tb00882.x10.1111/j.1151-2916.2001.tb00882.x ↗
26. 10.1021/es950391v10.1021/es950391v ↗
27. 10.1007/s10856-007-3068-810.1007/s10856-007-3068-8 ↗
28. Chen Y · Int J Nanomed · 2011 · 6 · 2321
29. 10.1039/c0jm00022a10.1039/c0jm00022a ↗
30. 10.1007/s10856-006-0040-y10.1007/s10856-006-0040-y ↗
31. 10.1002/jbm.a.3049610.1002/jbm.a.30496 ↗